Syngene International Ltd

For the second consecutive session, Syngene International Ltd has declined further, hitting a fresh 52-week low of Rs 374.1 on 18 Sep 2026, marking a significant 43.3% drop from its peak of Rs 678 within the last year.

For the eighth consecutive session, Syngene International Ltd has closed lower, culminating in a fresh 52-week low of Rs 374.35 on 16 Sep 2026. This marks a 44.7% decline from its 52-week high of Rs 678, underscoring sustained selling pressure despite a healthcare sector that has shown pockets of resilience.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Syngene International Ltd’s stock price declined to a fresh 52-week low of Rs.374.75 on 11 September 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a series of financial setbacks and valuation concerns.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish outlook. The company’s share price has declined by 1.62% on 7 Aug 2026, closing at ₹400.00, reflecting growing investor caution amid deteriorating technical parameters and underperformance relative to benchmark indices.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Despite a recent uptick in price, the stock remains under pressure with a strong sell rating and a deteriorating long-term outlook compared to benchmark indices.

Syngene International Ltd has been downgraded from a Sell to a Strong Sell rating as of 30 July 2026, reflecting a marked deterioration across key investment parameters including financial performance, quality metrics, valuation, and technical indicators. The healthcare services company’s recent quarterly results and market trends have raised significant concerns, prompting a reassessment of its investment appeal.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a marked shift in technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade to a Strong Sell by MarketsMOJO, coupled with a 3.58% decline in daily price, underscores growing investor caution amid weakening price action and subdued relative strength.

Syngene International Ltd, a key player in the Healthcare Services sector, has seen its quality rating downgraded from good to average, reflecting a notable deterioration in its business fundamentals. The downgrade comes amid a challenging financial performance marked by declining profitability, subdued growth, and a weakening return profile, raising concerns for investors amid a broader market that has outperformed the stock significantly over the past decade.

Syngene International Ltd., the contract research and manufacturing services provider, reported a staggering loss of ₹9.00 crores for Q1 FY27, marking a dramatic reversal from the ₹86.70 crores profit posted in Q1 FY26. The 110.38% year-on-year decline in profitability, coupled with a 15.84% revenue contraction, has sent the stock tumbling 4.27% to ₹396.00, extending its brutal year-to-date decline to 39.16%. With a market capitalisation of ₹15,985.30 crores, the company now trades at a precarious 47x trailing twelve-month earnings despite deteriorating fundamentals.

Syngene International Ltd’s stock price declined sharply on 30 Jul 2026, hitting a new 52-week low of Rs.376.9. This marks a significant drop for the healthcare services company, reflecting ongoing challenges in its financial performance and market positioning.

Syngene International Ltd experienced a sharp gap down at the opening on 30 July 2026, reflecting heightened market apprehension. The stock opened 7.4% lower, hitting a new 52-week low of Rs. 376.9, underperforming its sector and broader indices amid a backdrop of cautious sentiment.

Syngene International Ltd experienced significant intraday weakness on 30 Jul 2026, hitting a new 52-week low of Rs. 377.45 as the stock faced intense selling pressure and underperformed its sector and benchmark indices.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has exhibited a nuanced shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.81%, the stock’s broader technical indicators reveal a complex interplay of bullish and bearish signals, underscoring the challenges faced by investors amid a prolonged downtrend relative to benchmark indices.